Regulatory woes: Did a 3-year FDA delay doom Dendreon’s prostate cancer drug?

Did delays in winning FDA to approve for the innovative prostate cancer drug Provenge cause Dendreon to borrow so much money that the Seattle company now faces the possibility of defaulting on its debt? Joseph Gulfo, a doctor who has written a new book on the U...